Navigation Links
New medications show promise in treating drug-resistant prostate cancer
Date:4/7/2009

e mice," said Sawyers. "While treating these animals with bicalutamide produced a modest effect on their tumors, the new drugs caused the tumors to shrink dramatically, and in some animals almost completely," he said.

Sawyers said the new drugs bind tightly enough to the natural hormone-binding site on androgen receptors to prevent most of them from functioning even in cells with a lot of androgen receptors. Bicalutamide interferes with the receptor through a different mechanism, which backfires, when too much androgen receptor is present, Sawyers explained.

The promising laboratory studies led Medivation to license the drugs for commercial development, said Sawyers, who serves as a consultant to the company and would receive royalties on the drug should it prove to be successful.

The company chose to use MDV3100 for clinical studies, which began in 2007. In those initial studies, 30 men with antiandrogen-resistant prostate cancer received low doses of MDV3100. Twenty-two of those men showed a sustained decline in their blood levels of prostate specific antigen (PSA), an indication that their cancer was responding favorably to the drug. This trial is still under way, and results from a total of 140 patients receiving higher doses of the drug will be reported within the next year, said Sawyers.

Medivation has received permission from the Food and Drug Administration for a large clinical trial of MDV3100 on about 1,200 patients with antiandrogen-resistant disease. This study will assess MDV3100's effect on cancer survival and will take several years.

While these preliminary results are promising, Sawyers said his laboratory will continue to seek further improvements in drug therapy for prostate cancer. "There were some men in the initial trial in which the drug didn't work at all, and we want to find out why," he said. "It may be because the drug is not potent enough to overcome resistance due to androgen receptor overexpression. Or, it may b
'/>"/>

Contact: Jennifer Michalowski
michalow@hhmi.org
301-215-8576
Howard Hughes Medical Institute
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Device prevents potential errors in childrens medications
2. Study of successful drug targets could hasten development of new medications
3. Genetic variant mimics effect of heart failure medications
4. Hypertension and cholesterol medications present in water released into the St. Lawrence River
5. Innovative civil engineering application promises cleaner waters
6. New CPR promises better results by compressing abdomen, not Chest
7. Tiny tubes and rods show promise as catalysts, sunscreen
8. New genetic research into nicotine addiction shows promise for personalized treatment
9. Genetic ancestral testing cannot deliver on its promise, study warns
10. Sweet potato shines as new promise for small enterprise and hunger relief in developing countries
11. Summer-dormant tall fescue grass shows promise for pasture improvements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... China , 31 de julio de 2015 ... www.icg-10.org ) se celebrará por medio de BGI del 22 al ... . Este año, la conferencia celebra ... ICG se ha convertido en una de las reuniones anuales ... ser una de las reuniones más dinámicas, entusiastas y mejores ...
(Date:7/31/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... 62/198989 for ELECTRONIC CRYPTO-CURRENCY MANAGEMENT METHOD AND ... advance crypto-currencies such as Bitcoin into the consumer market ... to manage all payments.  The technology ...
(Date:7/30/2015)... , July 30, 2015 Cellecta, ... for gene function analysis and biomarker discovery, announced ... (sgRNA) Knockout Library targeting all human protein coding ... permanently "knock out" a gene,s function. Cellecta,s new ... high throughput screening tool so that researchers can ...
Breaking Biology News(10 mins):La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2
... In April 2010, the US government adopted a new nuclear ... defense systems will reliably protect the continental United States in ... Bulletin of Atomic Scientists , published by SAGE, shows ... and would not be effective in real combat conditions. ...
... the human immune system,s assassin a protein called perforin ... funded by the Biotechnology and Biological Sciences Research Council (BBSRC) ... where they used powerful electron microscopes to study the mechanism ... research is published today (1800hrs, 31 October) in Nature ...
... have discovered a new member of a gene family that ... weight. The gene is the third member of the agouti ... One helps determine skin and hair color, and the other ... new gene, called agrp2, has been found exclusively in bony ...
Cached Biology News:US nuclear safety claim is a 'dangerous fantasy' 2US nuclear safety claim is a 'dangerous fantasy' 3Immune system assassin's tricks visualised for the first time 2Newly discovered gene enables fish to 'disappear' 2
(Date:8/3/2015)... Md. , Aug. 3, 2015   Intrexon ... will release first half and second quarter 2015 financial ... th , 2015.  The Company will host a conference ... and provide a general business update. The ... US) and 1-412-902-4262 (International), and asking to join the ...
(Date:8/3/2015)... BC , Aug. 3, 2015 /PRNewswire/ - RepliCel Life ... medicine company focused on the development of autologous cell therapies, ... be presenting at the InvestMNT conference held in ... 8:15 AM local time. Hall,s presentation will highlight RepliCel,s 18-month ... sale in Europe , clinical data from ...
(Date:7/31/2015)... , July 31, 2015 In today,s ... that help them drive positive health outcomes, improve ... source of patient care in their communities. At ... tradeshow and conference, AmerisourceBergen announced a new set ... Services Administration Organization and help independent pharmacies endure ...
(Date:7/31/2015)... , July 31, 2015 China Cord Blood ... China,s leading provider of cord blood collection, ... storage services, today announced that the Company has filed ... Securities and Exchange Commission. The filed Form 20-F includes ... 31, 2015. The Form 20-F can be accessed by ...
Breaking Biology Technology:Intrexon to Announce First Half and Second Quarter 2015 Financial Results and Host Conference Call on August 10th 2RepliCel Presenting at InvestMNT Investor Conference in Minneapolis 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3China Cord Blood Corporation Files Its Annual Report on Form 20-F 2
... 2011) After Fukushima, it is now imperative to redefine ... to grave. If nuclear waste management is not thought out ... nuclear power as an energy choice, according to research that ... , published by SAGE. According to Allison Macfarlane, associate ...
... just fifteen minutes to analyze a sample suspected of ... The technology amplifies any anthrax DNA present in the ... microscopic cells of the deadly bacteria Bacillus anthracis. ... lethal microbe that might be used intentionally to infect ...
... significant threat to humans, as emphasized by the recent effects ... on July 21st by the Cell Press journal Developmental ... similar and divergent strategies that different toxins use to invade ... protein derived from the castor bean plant that has raised ...
Cached Biology Technology:Nuclear waste requires cradle-to-grave strategy 2Nuclear waste requires cradle-to-grave strategy 3Nano detector for deadly anthrax 2Targeting toxin trafficking 2
Rat polyclonal to acetyl Salicylic Acid ( Abpromise for all tested applications)....
Mouse monoclonal [DJR3] to DcR1 (Phycoerythrin) ( Abpromise for all tested applications). entrezGeneID: 8794 SwissProtID: O14798...
GBL Antibody...
Human acetylcholine receptor (AChR)-alpha. Exhibits homogenous, high affinity,binding to the receptor. Binds weakly to a64-78. Inhibits binding of many,myasthenia gravis sera to human AChR....
Biology Products: